Connect your AI

Alkermes ALKS Debt Issuance Costs

Debt Issuance Costs at other companies

Arrowhead ResearchARWR

$18.72M—

TG TherapeuticsTGTX

$2.6M—

BridgeBio PharmaBBIO

——

Other financials

Income statement

Revenue$392.9M+28.2%

Gross profit$331.3M+28.8%

Operating income-$48.3M-450%

Net income-$66.5M-396%

EPS (diluted)-$0.40-408%

Balance sheet

Cash & equivalents$351.6M-12.1%

Total debt$1.6B+2,034%

Total equity$1.8B+15.9%

Total assets$4.3B+105%

Cash flow

Operating cash flow-$165.7M-268%

CapEx$4.1M-59.5%

Free cash flow-$169.8M-291%

Valuation

Market cap$7.5B+9.7%

Enterprise value$8.73B+41.2%

P/E49.1×+29.7×

P/S4.8×+0.3×

Profitability

Gross margin86.6%+2.2pp

Operating margin12.3%-13.6pp

Net margin9.8%-13.5pp

FCF margin14.2%-17.6pp

Returns & leverage

Return on equity9.4%-16.1pp

Debt / equity0.9×+0.9×

Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alkermes's debt issuance costs?: Alkermes (ALKS) reported debt issuance costs of $1.61M in Q1 2026.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.